Operating Margin % is calculated as Operating Income divided by its Revenue. US Stem Cell's Operating Income for the
three
months ended in Dec. 2022 was $-0.37 Mil. US Stem Cell's Revenue for the
three
months ended in Dec. 2022 was $0.02 Mil. Therefore, US Stem Cell's Operating Margin % for the quarter that ended in Dec. 2022 was -1,870.00%.
The historical rank and industry rank for US Stem Cell's Operating Margin % or its related term are showing as below:
USRM's Operating Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -174.46 * Ranked among companies with meaningful Operating Margin % only.
US Stem Cell's 5-Year Average Operating Margin % Growth Rate was 0.00% per year.
US Stem Cell's Operating Income for the
three
months ended in Dec. 2022 was $-0.37 Mil.
Its Operating Income for the trailing twelve months (TTM) ended in Dec. 2022 was $-1.72 Mil.
US Stem Cell Operating Margin % Historical Data
The historical data trend for US Stem Cell's Operating Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of US Stem Cell's Operating Margin %
For the Biotechnology subindustry, US Stem Cell's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
US Stem Cell's Operating Margin % Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, US Stem Cell's Operating Margin % distribution charts can be found below:
* The bar in red indicates where US Stem Cell's Operating Margin % falls into.
US Stem Cell Operating Margin % Calculation
Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.
US Stem Cell's Operating Margin % for the fiscal year that ended in Dec. 2022 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
US Stem Cell (OTCPK:USRM) Operating Margin % Explanation
Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.
Be Aware
Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).
If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.
For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokias Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).
Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.
US Stem Cell Operating Margin % Related Terms
Thank you for viewing the detailed overview of US Stem Cell's Operating Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.
US Stem Cell Inc is a biotechnology company engaged in the discovery and development of autologous cell therapies for the treatment of chronic and acute heart damage. Its product includes MyoCell, a clinical therapy designed to populate regions of scar tissue within a patient's heart with autologous muscle cells, or cells from a patient's body, for the purpose of improving cardiac function in chronic heart failure patients. The company's discoveries include multiple cell therapies in various stages of development that repair damaged tissues throughout the body due to injury or disease so that patients may return to a normal lifestyle.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
USRM has been successfully added to your 